How pandemic challenges delayed FDA approvals

As the U.S. stretches for a July 4 goal of vaccinating 70% of adults against COVID-19, FDA is looking back at its performance during the pandemic and laying plans for the next phase. The agency has released reports on its success in meeting PDUFA and biosimilar use fee goals and the effect of the pandemic on inspections that are prerequisites for new medical product approvals.